GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsGuangzhou and London, 27 August2021–Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody t...
GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that the first patient has been dosed in a Phase III clinical study for BAT2206, a proposed biosimilar of Stelara® (u...
Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase III clinical study for BAT2506, a proposed biosimilar of Simponi® (golimumab). The ...
